

**News Release** 

Bayer AG Communications and Public Affairs 51368 Leverkusen Germany Tel. +49 214 30-1 www.news.bayer.com

## **Technology Can Help Improve Patient Safety: Health Experts**

Bayer Pakistan launches SafeTrack, a web-based digital platform for reporting adverse events – to mark International Patient Safety Day 2019

**Karachi, September 17, 2019** – Health experts in a panel discussion organized by Bayer Pakistan opined that the use of technology can help overcome challenges in patient safety. Lack of patient safety is the 14<sup>th</sup> leading cause of morbidity and mortality across the world according to a 2017 report by the Organisation for Economic Co-operation and Development (OECD).

The panel discussion was part of an event organized to mark International Patient Safety Day 2019, which calls for all stakeholders in health care systems to work together to improve patient safety, a goal which Bayer is committed to.

During the discussion, renowned medical practitioners and educationists including; Dr. Rafeeq Alam, Dean, Faculty of Pharmacy, Ziauddin University; Dr. Riaz Qureshi, Professor of Family Medicine, Aga Khan University Hospital (AKUH); Dr Abdul Basit Baig, Executive Director Quality and Monitoring Directorate; Dr. Waqar Ahmed, Assistant Director, DRAP Karachi, and Dr. Mahrukh Mughal, Assistant Director CDL, DRAP Karachi, shared their views on patient safety and discussed measures to improve awareness of key issues relating to patient safety amongst the public. These included the importance of taking prescription medication as prescribed, and the monitoring and timely reporting of any adverse events.

The panel urged medical practitioners, drug regulators from the Ministry of Health and health advisors/professionals to work together and spread awareness about patient safety and develop a mechanism to mitigate risks.

"The goal is to improve the health literacy of citizens and empower patients to be actively engaged in taking responsibility for their own health. In this regard, technological solutions such as SafeTrack, Bayer's new web-based tool, can go a long way toward promoting safety," said Dr. Syed Rizwan Ahmed, Pharmacovigilance Country Head at Bayer.

During the event, Bayer Pakistan announced the launch of SafeTrack, a new web-based, digital tool for the public which is designed to allow for easy, quick and convenient reporting of adverse events.

"As a leading pharmaceutical company, patient safety is one of Bayer's core values and our highest priority. This event, and the launch of SafeTrack, demonstrate Bayer's commitment to ensuring the

safety of current and future patients and consumers," said Dr. Imran Ahmad Khan, CEO and Managing Director, Bayer Pakistan.

"We hope that this Patient Safety Day event and panel discussion will encourage patient safety stakeholders to use SafeTrack, which provides a quick, easy and convenient way of reporting adverse events digitally back to us to help improve patient safety," he added.

"Our Pharmacovigilance colleagues work diligently at every stage of the product lifecycle to ensure that the benefits of our products outweigh the risks," Dr Imran Ahmad Khan continued, adding that Bayer Pakistan looks forward to working with relevant stakeholders in the country to improve patient safety.

The event, which was attended by media personnel, members of the public as well as Bayer employees, included an exhibition on patient safety and an interactive game on adverse event reporting.

## **About Bayer**

Bayer is a global enterprise with core competencies in the Life Science fields of health care and agriculture. Its products and services are designed to benefit people and improve their quality of life. At the same time, the Group aims to create value through innovation, growth and high earning power. Bayer is committed to the principles of sustainable development and to its social and ethical responsibilities as a corporate citizen. In fiscal 2017, the Group employed around 99,800 people and had sales of EUR 35.0 billion. Capital expenditures amounted to EUR 2.4 billion, R&D expenses to EUR 4.5 billion. For more information, go to www.bayer.com.

## Contact:

Hafsa Zubair, Head of Communications and Public Affairs

Phone: +92-21-111-000-227
Email: hafsa.zubair@bayer.com

## **Forward-Looking Statements**

This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer's public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.